Myocardial perfusion imaging: a plus for coronary risk classification in diabetics Albert Flotats Editorial Commentary 31 January 2012 Pages: 383 - 386
Myocardial perfusion imaging and risk classification for coronary heart disease in diabetic patients. The IDIS study: a prospective, multicentre trial Wanda AcampaMario PetrettaAlberto Cuocolo Original Article 23 November 2011 Pages: 387 - 395
Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice M. Hacker Editorial Commentary 22 December 2011 Pages: 396 - 398
The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers Yen-Wen WuHsian-Li KaoWei-Shiung Yang Original Article 23 November 2011 Pages: 399 - 407
The effect of device-based cardiac contractility modulation therapy on myocardial efficiency and oxidative metabolism in patients with heart failure Georg GoliaschAliasghar KhorsandSenta Graf Original Article 15 November 2011 Pages: 408 - 415
Microvascular dysfunction in nonfailing arrhythmogenic right ventricular cardiomyopathy Matthias PaulKambiz RahbarMichael Schäfers Short Communication 24 November 2011 Pages: 416 - 420
Ventricular dyssynchrony assessed by gated myocardial perfusion SPECT using a geometrical approach: a feasibility study Berlinda J. van der VeenImad Al YounisAlbert de Roos Original Article Open access 24 November 2011 Pages: 421 - 429
Downstream resource utilization following hybrid cardiac imaging with an integrated cadmium-zinc-telluride/64-slice CT device Michael FiechterJelena R. GhadriPhilipp A. Kaufmann Original Article 06 December 2011 Pages: 430 - 436
ST-segment depression during vasodilator stress is of minor clinical importance in women with normal myocardial perfusion imaging and low or intermediate risk of coronary artery disease Dimitris J. ApostolopoulosPeriklis DavlourosDimitrios Alexopoulos Original Article 08 December 2011 Pages: 437 - 445
Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients? Laura EvangelistaDomenico RubelloGiorgio Saladini Editorial Commentary 20 December 2011 Pages: 446 - 449
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study Nina Mortazavi-JehannoAnne-Laure GiraudetJean-Louis Alberini Original Article 20 December 2011 Pages: 450 - 460
18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster? Otto C. BoermanMartin Gotthardt Editorial Commentary Open access 15 December 2011 Pages: 461 - 462
18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma Dale O. KiesewetterHaokao GaoXiaoyuan Chen Original Article 15 December 2011 Pages: 463 - 473
Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer Anne-Sophie BatsFlorent HugonnetFabrice Lécuru Original Article 23 November 2011 Pages: 474 - 480
Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts Jennie MalmbergAnna PerolsAmelie Eriksson Karlström Original Article 30 November 2011 Pages: 481 - 492
18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation Thorsten DerlinChristoph WeberNicolaus Kröger Original Article 24 November 2011 Pages: 493 - 500
Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy Aurora Sainz-EstebanVikas PrasadRichard P. Baum Original Article 20 December 2011 Pages: 501 - 511
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET Saiyada N. F. RizviOtto J. VisserMark Lubberink Original Article Open access 05 January 2012 Pages: 512 - 520
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials Thida WinTryphon LambrouAshley M. Groves Original Article 30 November 2011 Pages: 521 - 528
Extremity doses of nuclear medicine personnel: a concern Gerrit J. KemerinkFilip VanhavereFelix M. Mottaghy Editorial Open access 15 November 2011 Pages: 529 - 532
Imaging the islet graft by positron emission tomography Olof ErikssonAbass Alavi Review Article 20 September 2011 Pages: 533 - 542
Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification Alexander KroissDaniel PutzerIrene Johanna Virgolini Letter to the Editor 12 January 2012 Pages: 543 - 543
Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies Paolo Zanotti-FregonaraRobert B. Innis Letter to the Editor 08 December 2011 Pages: 544 - 547
Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail Sauli SavolainenMark KonijnenbergGlenn Flux Letter to the Editor 13 January 2012 Pages: 548 - 549
Razelle Kurzrock, Maurie Markman (eds): Targeted Cancer Therapy Luigi MansiAndrea Vaccaro Book Review 05 October 2011 Pages: 550 - 551
Erratum to: Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset Angelina CistaroMaria Consuelo ValentiniMarco Pagani Erratum 16 December 2011 Pages: 552 - 552
18F-FDG PET to identify soft tissue disease in multiple myeloma Sharon F. HainSobia KhanWilliam Stevenson Image of the Month 14 October 2011 Pages: 553 - 554